Anaemia and cancer treatment: A conceptual change

Singapore Medical Journal

Volumn 49, Issue 10, 2008, Pages 759-764

  Khan, Farhat Aziz ^a   Shukla, A N ^b   Joshi, S C ^a  

^a ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

^b Palliative Care Unit   (Italy)

Author keywords

Anaemia; Cancer; Cancer related anaemia; Epoetin; Erythropoietin; Recombinant human erythropoietin

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; CANCER RADIOTHERAPY; CANCER SURVIVAL; HUMAN; PATHOGENESIS; PHENOTYPE; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANEMIA; ANOXIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; NEOPLASMS; QUALITY OF LIFE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 54949106168     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Groopman JE, Itri LM. Chemotherpy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-34.
2. Steensma DP. Management of anemia in patients with cancer. Curr Oncol Rep 2004; 6: 297-304.
3. Ludwig H, Birgegard G, Barrett-Lee P, et al. Prevalence and management of anaemia in patients with hematologic malignancies and solid tumors: results from the European Cancer Anaemia Survey (ECAS). Blood 2002; 100:234a-5a.
4. Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005; 97:489-98.
5. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004; 116 suppl 7A:11S-26S.
6. Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver and oncologist perceptions of cancer related fatigue: results of a tripart assessment survey. The fatigue coalition. Semin Hematol 1997; 34 suppl 2:4-12.
7. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5:353-60.
8. Skillings JR, Rogers-Melamed I, Nabholtz JM, et al. An epidemiological review of anaemia in cancer chemotherapy in Canada. Eur J Cancer 1995; 31A(5 suppl):5S.
9. Coiffier B, Guastalla JP, Pujade-Lauraine E, Bastit P; Anemia Study Group. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001; 37:1617-23.
10. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000; 26:303-11.
11. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966; 3:351-75.
12. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocyte cells. Blood 2003; 101:4148-54.
13. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004; 113:1251-3.
14. Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998; 174 suppl 4:13-6.
15. Kelleher DK, Matthiensen U, Thews O, Vaupel P. Blood flow, oxygenation and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996; 56:4728-34.
16. Hockel M, Schlenger K, Arral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56:4509-15.
17. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-9.
18. Höckel M, Schlenger K, Höckel S, et al. Association between tumor hypoxia and malignant progression: The clinical evidence in cancer of the uterine cervix. In: Vaupel P, Kelleher DK, eds. Tumor Hypoxia. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1999: 65-74.
19. Frommhold H, Guttenberger R, Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol 1998; 174 Suppl 4:31-4.
20. Girinski T, Pejovic-Lenfant MH, Bourhis J, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989; 16:37-42.
21. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of cervix. Cancer 1999; 86:1528-36.
22. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49:6449-65.
23. Pirollo KF, Bouker KB, Chang EH. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 2000; 11:419-32.
24. Teicher BA, Holden SA, al-Achi A, Herman TS. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSallC murine fibrosarcoma. Cancer Res 1990; 50:3339-44.
25. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20:4083-107.
26. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of the epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-74.
27. Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol 1992; 19(3 suppl 8):29-35.
28. Lavey RS, Dempsy WH. Erythropoietin increases hemoglobin in cancer patients during radiotherapy. Int J Radiol Oncol Biol Phys 1993; 27:1147-52.
29. Antonadou D, Cardamekis E, Sarris V, Tzigounia N. Effect of the administration of recombinant human erythropoetin in patients with pelvic malignancies during radiotherapy. Radiother Oncol 1998; 48:S122.
30. Glaser C, Millesi W, Gossweiner S, et al. Erythropoietin supply increases efficacy of neoadjuvant chemoradiotherapy inpatients of oral squamous cell carcinoma. Proc Am Soc Clin Oncol 1998; 17:397a.
31. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiotherapy either concomitantly or sequentially with chemotherapy. Blood 2000; 96:434a.
32. Glaser C, Millesi F, Wanschitz B, et al. R-HuErythropoietin treatment increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival of patients with oral squamous cell carcinoma: a 17-month follow-up. Proc Am Soc Clin Oncol 1999; 18: 399a.
33. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98:708-14.
34. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, qualitative review. Cancer 2001; 91:2214-21.
35. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48:198-206.
36. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disesase. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-14.
37. Moullet I, Salles G, Ketterer N, et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Annals of Oncol 1998; 9:1109-15.
38. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-60.
39. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23:5960-72.
40. Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24:4708-13.
41. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nat Clin Pract Oncol 2006; 3:152-64.
42. Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005; 41:1140-9.
43. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anaemia associated with multiple myeloma or non Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995; 86:4446-53.
44. Cazzola M, Ponchio L, Pedrotti C, et al. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica 1996; 81:434-41.
45. Osterborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood 1996; 87:2675-82.
46. Stasi R, Brunetti M, Bussa S, et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 1997; 3:733-9.
47. Littlewood TJ, Zagari M, Pallister C, Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in cancer patients. Oncologist 2003; 8:99-107.